Aberdeen Group plc has announced an increase in its ownership stake in Immunic, Inc. to 7.99%. This update, filed on November 2, 2026, is significant as it demonstrates Aberdeen's continued investment strategy in the pharmaceutical preparations sector.

Aberdeen Group plc, incorporated in the United Kingdom, is a prominent player in investment management. The company has a history of making strategic investments across various sectors, including pharmaceuticals. The recent filing indicates a growing confidence in Immunic, Inc., a company focused on developing therapies for autoimmune diseases.

The filing reveals that Aberdeen Group beneficially owns 1,090,427 shares of Immunic, Inc., with shared voting and dispositive power. This stake reflects a strategic alignment with Immunic's goals and potential growth in the pharmaceutical preparations market.

As a result of this increased ownership, Aberdeen Group may influence Immunic's strategic decisions and market positioning. This move could impact other stakeholders and competitors within the pharmaceutical industry, highlighting the competitive landscape in which Immunic operates.

Details were not available in the SEC filing regarding future actions or plans following this increase in ownership. However, the filing does indicate that the shares were acquired in the ordinary course of business and not for the purpose of influencing control over Immunic, Inc.